DOCSLIB.ORG

Glossary of Terms

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Glossary of Terms 1 Glossary of Terms Breast Module Adjuvant breast Radiation therapy given after primary cancer radiation treatment to increase the chances of cure, or decrease the risk of local recurrence. Anthracycline An antibiotic, such as daunorubicin®, doxorubicin®, chemotherapy and epirubicin®, that is made from the fungus Streptococcus peucetius and used for cancer treatment. Aromatase inhibitors Many breast tumours are ‘estrogen sensitive’, (AIs) meaning that the hormone estrogen enhances their growth. Aromatase inhibitors such as anastrazole (Arimidex®), exemestane (Aromasin®), and letrozole (Femara®) can block the growth of these tumours by lowering the amount of estrogen in the body. Ascites Abnormal accumulation of serous fluid in the spaces between tissues and organs in the cavity of the abdomen (also called hydroperitoneum). BRCA 1 A tumour-suppressor gene that repairs chromosomal damage, thereby regulating the cycle of cell division by preventing cells from growing and dividing too rapidly or in an uncontrolled way. Certain mutations confer a high probability (85% lifetime risk) of developing breast cancer, and others cause ovarian cancer. Familial mutations of this gene are particularly common among people in the Ashkenazi Jewish ethnic group. BRCA2 A tumour-suppressor gene that repairs chromosomal damage, thereby regulating the cycle of cell division by keeping cells from growing and dividing too rapidly or in an uncontrolled way. Mutations of the BRCA2 gene appear to confer a high risk of early onset breast cancer, but do not carry a substantial elevated risk of ovarian cancer. Calcification Deposits of calcium in the tissues; calcification in the breast can be seen on a mammogram, but cannot be detected by touch. There are two types of breast calcification: macrocalcification and microcalcification. www.radiationoncology.ca Virtual Experience in Radiation Oncology © 2008 2 Macrocalcifications are large deposits and are usually not related to cancer. Microcalcifications are specks of calcium that may be found in an area of rapidly dividing cells. Many microcalcifications clustered together may be a sign of cancer. Clinical target volume Tumour volume that contains the Gross Target (CTV) Volume (GTV) and subclinical microscopic disease. Core biopsy A procedure in which a needle is used to remove a sample of breast tissue or fluid for examination under a microscope. Digitally reconstructed A computer-generated projection image obtained radiograph (DRR) from CT data that serves as a reference for transferring a 3-D treatment plan to the clinical treatment setting. Ductal carcinoma in A noninvasive, precancerous condition in which situ (DCIS) abnormal cells are found in the lining of a breast duct. The abnormal cells have not spread outside the duct to other tissues in the breast. In some cases, DCIS may become invasive cancer and spread to other tissues, although it is not known at this time how to predict which lesions will become invasive. DCIS is also called intraductal carcinoma. Edema An accumulation of an excessive amount of watery fluid in cells, tissues, or serous cavities. Erythema Abnormal redness of the skin due to capillary congestion and dilation; often a sign of inflammation or infection. Estrogen receptors Intracellular protein molecules containing a specific site to which estrogens (or closely related molecules) can bind. Target tissues affected by estrogen molecules all contain estrogen receptors; other organs and tissues in the body do not. These proteins are present in many breast cancer cells and are important in the progression of hormone-dependent cancers. Gross tumour volume Gross palpable or visible extent and location of (GTV) malignant growth. Hormone receptor Indicates the presence or absence of hormone status receptors. A cancer is called ‘ER-positive’ if it has receptors for the hormone estrogen. It is called ‘PR- www.radiationoncology.ca Virtual Experience in Radiation Oncology © 2008 3 positive’ if it has receptors for the hormone progesterone. Cells lacking such receptors are considered ‘negative’ for these hormones. Hyperpigmentation Excess pigment in skin or tissue. Invasive cancer Invasive or infiltrating cancer that has spread beyond the layer of tissue in which it developed and is growing into surrounding tissues. Isodose distribution A ‘map’ of radiation doses across the volume of tissue being treated. Linear accelerator A radiation therapy treatment machine that (“Linac”) accelerates electrons, creating high-energy radiation to treat cancers. Also called a “linac”. Lobule A rounded projection or subdivision of a lobe. In the breast, lobules produce milk. Lumpectomy Surgery to remove a breast tumour and a small amount of surrounding normal tissue. Lymphedema Lymphedema occurs when lymphatic fluid builds up in the soft tissues of the body, due to an injury or blockage of the lymphatic system. It can occur as a result of cancer or after surgery or radiation treatment for cancer, particularly when lymph nodes are removed or damaged. Mastectomy Surgical removal of all or part of the breast and sometimes associated lymph nodes and muscles. Metastasis The spread of cancerous cells from the initial area to other parts of the body. A tumour formed by cells that have spread is called a “metastatic tumour” or a “metastasis”. A metastatic tumour contains cells that are like those in the original (primary) tumour. The plural form of metastasis is metastases. Neo-adjuvant Chemotherapy given before the primary treatment. chemotherapy Photon A quantum of electromagnetic radiation; the elementary particle of photon radiation therapy. X rays and gamma rays are photon radiation. Planning target The geometric radiation target where dose is to be volume (PTV) delivered. The PTV contains the Clinical Target Volume (CTV) plus a margin around it to allow for treatment setup variation and internal target motion. www.radiationoncology.ca Virtual Experience in Radiation Oncology © 2008 4 Portal imaging The documentation of treatment fields through radiographic images or electronic portal imaging devices. Radiation pneumonitis An interstitial pulmonary inflammation developing in as many as 5-15% of patients with thoracic irradiation, for example due to breast and lung cancer. Acute radiation pneumonitis tends to occur within 6 months following treatment. Sentinel node biopsy A sentinel lymph node (SLN) is the first lymph node to which cancer cells are likely to spread from the primary tumor. Cancer cells may appear in the sentinel node before spreading to other lymph nodes, and a biopsy or sample of these nodes can be used to help determine the extent or stage of cancer. Side effects Symptoms directly related to treatment, such as nausea resulting from radiation treatment of the stomach. Side effects are considered acute if they occur within the first six months after treatment. Symptoms persisting over a longer period of time are considered chronic. Simulation A simulation machine (simulator) is a radiographic X machine/CT-simulator ray unit that mimics all the movements and parameters of actual treatment units. A CT-simulator is a computerized tomography scanner specifically designed for treatment planning. Staging Assessing the extent of the primary tumour and whether there is spread of cancer to the draining lymph nodes or distant body sites. Systemic treatment Treatment using substances that travel through the bloodstream. Tamoxifen An anti-estrogen drug used to treat breast cancer and to prevent it in women who are at high risk of developing breast cancer. Tamoxifen blocks the effects of the hormone estrogen in the breast. Tangents A parallel-opposed pair of treatment beams that treats a curved volume, such as the breast along an angle that is tangential to the chest wall. Tumour grade A measure of the degree of severity of a cancer tumour; the grade of a tumour depends on how abnormal the cancer cells look under a microscope www.radiationoncology.ca Virtual Experience in Radiation Oncology © 2008 5 and how quickly the tumour is likely to grow and spread. UICC - Union The mission of the International Union Against Cancer Internationale Contre is to build and lead the global community engaged in Le Cancer sharing and exchanging cancer control knowledge and competence equitably; transferring scientific findings to clinical settings; systematically reducing and eventually eliminating disparities in prevention, early detection, treatment and care of cancers, and delivering the best possible care to all cancer patients. www.radiationoncology.ca Virtual Experience in Radiation Oncology © 2008 .
Load more

Recommended publications
  • Abnormal Pap Smear
    9195 Grant Street, Suite 410 300 Exempla Circle, Suite 470 6363 West 120th Avenue, Suite 300 Thornton, CO 80229 Lafayette, CO 80026 Broomfield, CO 80020 Phone: 303-280-2229(BABY) 303-665-6016 303-460-7116 Fax: 303-280-0765 303-665-0121 303-460-8204 www.whg-pc.com Abnormal Pap Smear The Pap test (also called a Pap smear) is a way to examine cells collected from the cervix and vagina. This test can show the presence of infection, inflammation, abnormal cells, or cancer. Regular Pap tests are an important step to the prevention of cervical cancer. Approximately 15,000 American women are diagnosed with cervical cancer each year and about 5,000 die of the disease. In areas of the world where Pap tests are not widely available, cervical cancer is a leading cause of cancer deaths in women. A Pap smear can assist your doctor in catching cervical cancer early. Early detection of cervical dysplasia (abnormal cells on the cervix) and treatment are the best ways to prevent the development of cervical cancer. What do abnormal Pap smear results mean? Abnormal Pap smear results can indicate mild or serious abnormalities. Most abnormal cells on the surface of the cervix are not cancerous. It is important to remember that abnormal conditions do not always become cancerous, and some conditions are more of a threat than others. There are several terms that may be used to describe abnormal results. • Dysplasia is a term used to describe abnormal cells. Dysplasia is not cancer, although it may develop into cancer of the cervix if not treated.
    [Show full text]
  • ASCO Answers: Testicular Cancer
    Testicular Cancer What is testicular cancer? Testicular cancer begins when healthy cells in 1 or both testicles change and grow out of control, forming a mass called a tumor. Most testicular tumors develop in germ cells, which produce sperm. These tumors are called germ cell tumors and are divided into 2 types: seminoma or non- seminoma. A non-seminoma grows more quickly and is more likely to spread than a seminoma, but both types need immediate treatment. What is the function of the testicles? The testicles, also called the testes, are part of a man’s reproductive system. Each man has 2 testicles. They are located under the penis in a sac-like pouch called the scrotum. The testicles make sperm and testosterone. Testosterone is a hormone that plays a role in the development of a man’s reproductive organs and other characteristics. What does stage mean? The stage is a way of describing where the cancer is located, if or where it has spread, and whether it is affecting other parts of the body. There ONCOLOGY. CLINICAL AMERICAN SOCIETY OF 2004 © LLC. EXPLANATIONS, MORREALE/VISUAL ROBERT BY ILLUSTRATION are 4 stages for testicular cancer: stages I through III (1 through 3) plus stage 0 (zero). Stage 0 is called carcinoma in situ, a precancerous condition. Find more information about these stages at www.cancer.net/testicular. How is testicular cancer treated? The treatment of testicular cancer depends on the type of tumor (seminoma or non-seminoma), the stage, the amount of certain substances called serum tumor markers in the blood, and the person’s overall health.
    [Show full text]
  • Precancerous Diseases of Maxillofacial Area
    PRECANCEROUS DISEASES OF MAXILLOFACIAL AREA Text book Poltava – 2017 0 МІНІСТЕРСТВО ОХОРОНИ ЗДОРОВ’Я УКРАЇНИ ВИЩИЙ ДЕРЖАВНИЙ НАВЧАЛЬНИЙ ЗАКЛАД УКРАЇНИ «УКРАЇНСЬКА МЕДИЧНА СТОМАТОЛОГІЧНА АКАДЕМІЯ» АВЕТІКОВ Д.С., АЙПЕРТ В.В., ЛОКЕС К.П. AVETIKOV D.S., AIPERT V.V., LOKES K.P. Precancerous diseases of maxillofacial area ПЕРЕДРАКОВІ ЗАХВОРЮВАННЯ ЩЕЛЕПНО-ЛИЦЕВОЇ ДІЛЯНКИ Навчальний посібник Text-book Полтава – 2017 Poltava – 2017 1 UDK 616.31-006 BBC 56.6 A 19 It is recommended by the Academic Council of the Higher state educational establishment of Ukraine "Ukrainian medical stomatological academy" as a textbook for English-speaking students of higher education institutions of the Ministry of Health of Ukraine (Protocol № 3, 22.11.2017). Writing Committee D.S. Avetikov – doctor of medicsl science, professor, chief of department of surgical stomatology and maxillo-facial surgery with plastic and reconstructive surgery of head and neck of the Higher state educational establishment of Ukraine ―Ukrainian medical stomatological academy‖. V.V. Aipert – candidate of medical science, assistant professor of department of surgical stomatology and maxillo-facial surgery with plastic and reconstructive surgery of head and neck of the Higher state educational establishment of Ukraine ―Ukrainian medical stomatological academy‖ K.P. Lokes - candidate of medical science, associate professor of department of surgical stomatology and maxillo-facial surgery with plastic and reconstructive surgery of head and neck of the Higher state educational establishment of Ukraine ―Ukrainian medical stomatological academy‖ Reviewers: R. Z. Ogonovski, doctor of medicsl science, professor, chief of department of surgical stomatology and maxillo-facial surgery ―Lviv national medical university named of D.Galicky‖. Y.P.
    [Show full text]
  • Polypoid Lesions Detected in the Upper Gastrointestinal Endoscopy: a Retrospective Analysis in 19560 Patients, a Single-Center Study of a 5-Year Experience in Turkey
    Orıgınal Article GASTROENTEROLOGY North Clin Istanb 2021;8(2):178–185 doi: 10.14744/nci.2020.16779 Polypoid lesions detected in the upper gastrointestinal endoscopy: A retrospective analysis in 19560 patients, a single-center study of a 5-year experience in Turkey Atilla Bulur,1 Kamil Ozdil,2 Levent Doganay,2 Oguzhan Ozturk,2 Resul Kahraman,2 Hakan Demirdag,2 Zuhal Caliskan,2 Nermin Mutlu Bilgic,2 Evren Kanat,3 Ayca Serap Erden,4 H. Mehmet Sokmen5 1Department of Gastroenterology, Yeni Yuzyil University Faculty of Medicine, Gaziosmanpasa Hospital, Istanbul, Turkey 2Department of Gastroenterology, Health Sciences University, Umraniye Training and Research Hospital, Istanbul, Turkey 3Gastroenterology Center, Batman, Turkey 4Department of Internal Medicine, Amasya University Faculty of Medicine, Sabuncuoglu Serefeddin Training and Research Hospital, Amasya, Turkey 5Department of Gastroenterology, Private Central Hospital, Istanbul, Turkey ABSTRACT OBJECTIVE: In our study, we aimed to evaluate the endoscopic features such as prevalence and localization of polypoid lesions determined by us using esophagogastroduodenoscopy and histopathological characteristics of biopsy specimens taken in detail. METHODS: The data of 19,560 patients undergoing upper gastrointestinal endoscopy for any reason between 2009 and 2015 in our endoscopy unit were screened retrospectively and endoscopic and histopathological findings were analyzed in detail. RESULTS: In our study, the polypoid lesion was detected in 1.60% (n=313) of 19,560 patients. The most common localization of the polypoid lesions was determined to be gastric localization (n=301, 96.2%) and antrum with a rate of 33.5% (n=105). When 272 patients in whom biopsy specimen could be taken was investigated, the most frequently seen lesion was polyp (n=115, 43.4%).
    [Show full text]
  • Pigmented Precancerous and Cancerous Changes in the Skin
    Pigmented Precancerous and Cancerous Changes in the Skin V. R. Khanolkar, M.D. (From lke Tata Memorial Hospital, Bombay, India) (Received for publication May 20, 1947) The changes to be described here concern pig- The present study is based on tumors from 15 mented Bowen's disease, squamous-cell carcinoma patients seen by us during the last 5 years at the and basal-cell carcinoma of skin. They do not in- Tata Memorial Hospital. Four of them showed clude the group of melanoma, melano-epithelioma multiple lesions, and will be considered separately or melano-carcinoma, nor the pigmentation in from the rest. The following table summarises in- conditions sometimes leading to cancer, such as, formation regarding age, sex, location etc. in the senile keratosis, keratosis resulting from arsenic, remaining 7 out of the first group of 11 cases. tar or radiation and xeroderma pigmentosum. These tumors were all deeply pigmented and The changes described in this paper have not at- histologically presented the structure of a basal- tracted enough attention of dermatologists, and cell or a basal-squamous type of carcinoma. They Eller and Anderson (8) have stated that pig- were similar in so many features, that only 4 out of mented basal cell carcinomas were "quite un- 11 have been described as illustrating their prob- common." At a recent symposium on "Malignant able mode of evolution. Case No. Nationality Age Sex Site Duration Diagnosis 1 Muslim 45 M Chin 1 year Basal sq. cell ca 2 Parsee 60 M Scalp 5 years Basal cell ca 3 Hindu 38 M Leg Mole since childhood, recent Basal cell ca (Deccani) growth 3 weeks 4 Hindu 54 M Forehead 8 years Basal cell ca (Gujarati) 5 Parsee 73 M Nasolabial fold 4 years Basal sq.
    [Show full text]
  • Review Article Cellular and Molecular Pathology of Gastric Carcinoma And
    S.-C.Gastric Ming: Cancer Pathology (1998) and1: 31–50 genetics of gastric cancer 31 1998 by International and Japanese Gastric Cancer Associations Review article Cellular and molecular pathology of gastric carcinoma and precursor lesions: A critical review Si-Chun Ming Department of Pathology and Laboratory Medicine, Temple University School of Medicine, 3400 North Broad Street, Philadelphia, Pennsylvania 19140, USA Abstract: Key words: stomach carcinoma, pathology, genetics The cellular and molecular pathology of gastric cancer and its precursors are reviewed and discussed. Gastric carcinogenesis is a multistep phenomenon, beginning with precancerous con- ditions. Among these, adenoma is a direct precursor, because Introduction of the dysplastic nature of its cells. However, gastric adenoma is relatively rare. Chronic atrophic gastritis (CAG) is the most Gastric cancer is one of the leading causes of cancer common precancerous condition, in which intestinal metapla- death throughout the world, although its incidence has sia often occurs. Carcinoma develops in CAG through stages declined in many countries. The cause of the decline has of hyperplasia and dysplasia involving both metaplastic and not been elucidated. The influence of environmental non-metaplastic glands. Molecular alterations, including repli- cation error and p53 and APC gene mutation and aneuploidy factors, including changes in life-style and eating habits, have been found in some of these conditions, confirming their remains significant. role in carcinogenesis. Carcinomas of the stomach are hetero- The etiology of gastric cancer is still unclear. The geneous in cellular composition. Both intestinal and gastric possibilities have expanded to include infectious agents, types of cells are found in all types of tumors, indicating the notably Helicobacter pylori.
    [Show full text]
  • Vaginal Cancer
    VAGINAL CANCER The Facts Vaginal cancer is a rare cancer of the female reproductive system. Around 15 women are diagnosed with it every year in Ireland. The vagina is part of the female reproductive system. It is a muscular tube about 10cm long. It is the passage between the opening of the womb (cervix) and the vulva. The vagina is the opening that allows blood to drain out each month during your menstrual period. The walls of the vagina are normally in a relaxed state. The vagina opens and expands during sexual intercourse and it stretches during childbirth to allow the baby to come out. Symptoms It’s rare to have symptoms if you have pre-cancerous cell changes in the lining of the vagina, called vaginal intraepithelial neoplasia (VAIN). As many as 20 in 100 women (20%) diagnosed with vaginal cancer don’t have symptoms at all. Your doctor may pick up signs of VAIN or very early vaginal cancer during routine cervical screening. However, around 80 out of 100 women (80%) with vaginal cancer have one or more symptoms. These can include: • bleeding in between periods or after the menopause • bleeding after sex • vaginal discharge that smells or is blood stained • pain during sexual intercourse • a lump or growth in the vagina that you or your doctor can feel • a vaginal itch that won’t go away Remember that many of these symptoms can also be caused by other conditions, such as infection. VAGINAL CANCER Risk Factors Although the exact cause of vaginal cancer isn't known, certain factors appear to increase your risk of the disease, including: • Increasing age: The risk of vaginal cancer increases with age, though it can occur at any age.
    [Show full text]
  • Management of Epithelial Precancerous Conditions
    Guideline Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019 Authors Pedro Pimentel-Nunes1,2,3, Diogo Libânio1,2, Ricardo Marcos-Pinto2,4, Miguel Areia2,5,MarcisLeja6, Gianluca Esposito7, Monica Garrido4, Ilze Kikuste6, Francis Megraud8, Tamara Matysiak-Budnik9, Bruno Annibale7, Jean-Marc Dumonceau10, Rita Barros11,12,Jean-FrançoisFléjou13, Fátima Carneiro11,12,14, Jeanin E. van Hooft15, Ernst J. Kuipers16, Mario Dinis-Ribeiro1,2 Institutions 13 Service d’Anatomie Pathologique, Hôpital Saint- 1 Gastroenterology Department, Portuguese Oncology Antoine, AP-HP, Faculté de Médecine Sorbonne Institute of Porto, Portugal Université, Paris, France 2 Center for Research in Health Technologies and 14 Pathology Department, Centro Hospitalar de São João Information Systems (CINTESIS), Faculty of Medicine, and Faculty of Medicine, Porto, Portugal Porto, Portugal 15 Department of Gastroenterology and Hepatology, 3 Surgery and Physiology Department, Faculty of AmsterdamUMC,UniversityofAmsterdam,The Medicine of the University of Porto, Porto, Portugal, Netherlands 4 Department of Gastroenterology, Porto University 16 Department of Gastroenterology and Hepatology, Hospital Centre, Institute of Biomedical Sciences, Erasmus MC University Medical Center, Rotterdam, University of Porto (ICBAS/UP),
    [Show full text]
  • Management of Juvenile Polyposis Syndrome in Children
    SOCIETY PAPER Management of Juvenile Polyposis Syndrome in Children and Adolescents: A Position Paper From the ESPGHAN Polyposis Working Group ÃShlomi Cohen, yWarren Hyer, z§Emmanuel Mas, jjMarcus Auth, ôThomas M. Attard, #Johannes Spalinger, yAndrew Latchford, and ÃÃCarol Durno ABSTRACT 02/28/2019 on BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3iUOEA+UwZl4WrbAahuvXsU1ZYmBAUBrDV9S3b4rWUow= by https://journals.lww.com/jpgn from Downloaded Downloaded The European Society for Paediatric Gastroenterology, Hepatology and What Is Known from Nutrition (ESPGHAN) Polyposis Working Group developed recommenda- https://journals.lww.com/jpgn tions to assist clinicians and health care providers with appropriate man- agement of patients with juvenile polyposis. This is the first juvenile There are no prior published guidelines specifically polyposis Position Paper published by ESPGHAN with invited experts. for children at risk, or affected by juvenile polyposis Many of the published studies were descriptive and/or retrospective in syndrome. nature, consequently after incorporating a modified version of the GRADE In paediatric practice, timing of diagnosis, age, and frequency of endoscopy are not standardized, and will by system many of the recommendations are based on expert opinion. This BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3iUOEA+UwZl4WrbAahuvXsU1ZYmBAUBrDV9S3b4rWUow= ESPGHAN Position Paper provides a guide for diagnosis, assessment, and vary across clinicians, and between different countries. management of juvenile polyposis syndrome in children and adolescents, Currently clinical practice is based on case series and and will be helpful in the appropriate management and timing of procedures the clinicians’ personal exposure to juvenile polyposis in children and adolescents. The formation of international collaboration and patients. consortia is proposed to monitor patients prospectively to advance our understanding of juvenile polyposis conditions.
    [Show full text]
  • Pleiotropic Regulators Driving Sequential Genetic And
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by SZTE Publicatio Repozitórium - SZTE - Repository of Publications Rev. Med. Virol. Published online in Wiley Online Library (wileyonlinelibrary.com) Reviews in Medical Virology DOI: 10.1002/rmv.1864 REVIEW Wild type HBx and truncated HBx: Pleiotropic regulators driving sequential genetic and epigenetic steps of hepatocarcinogenesis and progression of HBV-associated neoplasms Hans Helmut Niller1*, Eva Ay2, Ferenc Banati3, Anett Demcsák4, Maria Takacs5 and Janos Minarovits4 1Institute for Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany 2Department of Retrovirology, National Center for Epidemiology, Budapest, Hungary 3RT-Europe Nonprofit Research Center, Mosonmagyarovar, Hungary 4University of Szeged, Faculty of Dentistry, Department of Oral Biology and Experimental Dental Research, Szeged, Hungary 5Division of Virology, National Center for Epidemiology, Budapest, Hungary SUMMARY Hepatitis B virus (HBV) is one of the causative agents of hepatocellular carcinoma. The molecular mechanisms of tumorigenesis are complex. One of the host factors involved is apparently the long-lasting inflammatory reaction which accompanies chronic HBV infection. Although HBV lacks a typical viral oncogene, the HBx gene encoding a pleiotropic regulatory protein emerged as a major player in liver carcinogenesis. Here we review the tumorigenic functions of HBx with an emphasis on wild type and truncated HBx variants, and their role in the transcriptional dysregulation and epigenetic reprogramming of the host cell genome. We suggest that HBx acquired by the HBV genome during evolution acts like a cellular proto-onc gene that is activated by deletion during hepatocarcinogenesis. The resulting viral oncogene (v-onc gene) codes for a truncated HBx protein that facilitates tumor progression.
    [Show full text]
  • Understanding Vulvar and Vaginal Cancers a Guide for People with Cancer, Their Families and Friends
    Understanding Vulvar and Vaginal Cancers A guide for people with cancer, their families and friends Cancer information For information & support, call Understanding Vulvar and Vaginal Cancers A guide for people with cancer, their families and friends First published November 2011. This edition October 2020. © Cancer Council Australia 2020. ISBN 978 1 925651 97 3 Understanding Vulvar and Vaginal Cancers is reviewed approximately every two years. Check the publication date above to ensure this copy is up to date. Editors: Rosemary McDonald and Ruth Sheard. Designer: Eleonora Pelosi. Printer: SOS Print + Media Group. Acknowledgements This edition has been developed by Cancer Council NSW on behalf of all other state and territory Cancer Councils as part of a National Cancer Information Subcommittee initiative. We thank the reviewers of this booklet: A/Prof Alison Brand, Director, Gynaecological Oncology, Westmead Hospital, NSW; Ellen Barlow, Clinical Nurse Consultant, Royal Hospital for Women, NSW; Jane Conroy-Wright, Consumer; Rebecca James, 13 11 20 Consultant, Cancer Council SA; Suparna Karpe, Clinical Psychologist, Gynaecological Oncology, Westmead Hospital, NSW; Dr Pearly Khaw, Consultant Radiation Oncologist, Peter MacCallum Cancer Centre, VIC; Sally McCoull, Consumer; A/Prof Orla McNally, Gynaecological Oncologist and Director, Oncology/Dysplasia, The Royal Women’s Hospital, and Director, Gynaecology Tumour Stream, Victorian Comprehensive Cancer Centre, VIC; Haley McNamara, Social Worker and Project Manager, Care at End of Life Project, Queensland Health, QLD; Tamara Wraith, Senior Clinician – Physiotherapy, The Royal Women’s Hospital, VIC. We also thank the health professionals, consumers and editorial teams who have worked on previous editions of this title. This booklet is funded through the generosity of the people of Australia.
    [Show full text]
  • Overview of Oral Potentially Malignant Disorders: from Risk Factors to Specific Therapies
    cancers Review Overview of Oral Potentially Malignant Disorders: From Risk Factors to Specific Therapies Luigi Lorini 1, Coro Bescós Atín 2, Selvam Thavaraj 3 , Urs Müller-Richter 4 , Margarita Alberola Ferranti 5, Jorge Pamias Romero 2, Manel Sáez Barba 2, Alba de Pablo García-Cuenca 2, Irene Braña García 6, Paolo Bossi 1 , Paolo Nuciforo 7 and Sara Simonetti 7,* 1 Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, ASST Spedali Civili of Brescia, University of Brescia, 25123 Brescia, Italy; [email protected] (L.L.); [email protected] (P.B.) 2 Oral and Maxillofacial Department, Vall d’Hebron University Hospital, 08035 Barcelons, Spain; [email protected] (C.B.A.); [email protected] (J.P.R.); [email protected] (M.S.B.); [email protected] (A.d.P.G.-C.) 3 Head and Neck Pathology, Guy’s and St Thomas’ NHS Foundation Trust, London SE1 9RS, UK; [email protected] 4 Comprehensive Cancer Center and Department of Oral and Maxillofacial Plastic Surgery, University Hospital of Würzburg, 97070 Würzburg, Germany and Bavarian Centre for Cancer Research, 97070 Würzburg, Germany; [email protected] 5 Department of Pathology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain; [email protected] 6 Department of Medical Oncology, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain; [email protected] 7 Citation: Lorini, L.; Bescós Atín, C.; Molecular Oncology Laboratory, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain; Thavaraj, S.; Müller-Richter, U.; [email protected] Alberola Ferranti, M.; Pamias Romero, * Correspondence: [email protected]; Tel.: + 34-93-254-34-50 J.; Sáez Barba, M.; de Pablo García-Cuenca, A.; Braña García, I.; Simple Summary: Oral potentially malignant disorders (OPMDs) include a group of oral mucosal Bossi, P.; et al.
    [Show full text]